CORRECTION OF EXPERIMENTAL L-NAME-INDUCED PRE-ECLAMPSY BY INHIBITOR OF ARGINASE L-NORVALINE AND ITS COMBINATIONS WITH PREPARATIONS OF STANDARD TREATMENT SCHEME

CORRECTION OF EXPERIMENTAL L-NAME-INDUCED PRE-ECLAMPSY BY INHIBITOR OF ARGINASE L-NORVALINE AND ITS COMBINATIONS WITH PREPARATIONS OF STANDARD TREATMENT SCHEME

Experimental L-NAME-induced pre-eclampsia model in rats was achieved by L-NAME administration from 14 to 20 pregnancy days. Blood pressure elevation, gestational proteinuria, placenta microcirculation impairing, vascular tone dysregulation, and L-norvaline (10 mg/kg) and conventional medications (me...

Full description

Bibliographic Details
Main Authors: O. S. Poljanskaja, M. V. Pokrovsky
Format: Article
Language:Russian
Published: Ministry of Healthcare of the Russian Federation. “Kuban State Medical University” 2014-02-01
Series:Кубанский научный медицинский вестник
Subjects:
крысы
преэклампсия
l-name
лечение
rats
pre-eclampsia
treatment
Online Access:https://ksma.elpub.ru/jour/article/view/38
Description
Summary:Experimental L-NAME-induced pre-eclampsia model in rats was achieved by L-NAME administration from 14 to 20 pregnancy days. Blood pressure elevation, gestational proteinuria, placenta microcirculation impairing, vascular tone dysregulation, and L-norvaline (10 mg/kg) and conventional medications (methyldopa 0,086 mg/kg/day & amlodipine 0,5 mg/kg) result in the evident correction of the pathological changes in pre-eclampsia model. Despite good L-norvaline with conventional pre-eclampsia medications). This might be explained by different points of applications and allows to affect many different patho-genesis chains.
ISSN:1608-6228
2541-9544

Similar Items